Systemic Therapies for Steroid-Refractory cGVHD: Second Line and Beyond
Panelists discuss how belumosudil is particularly effective for patients with lung involvement due to its antifibrotic mechanism.
Case Progression and Treatment Selection
This segment returns to the clinical case of a 50-year-old woman with chronic GVHD who, after initial improvement on ruxolitinib and steroids, experiences progression with worsening pulmonary symptoms, new sclerotic skin changes, and liver abnormalities.
The panel discusses factors influencing post–ruxolitinib therapy selection. There is consensus that belumosudil would be appropriate given its:
- Antifibrotic mechanism potentially beneficial for lung involvement
- Data supporting efficacy in bronchiolitis obliterans
- Generally good tolerability with minimal liver issues
The panel also discusses cytopenia management in chronic GVHD, noting that while ruxolitinib may contribute to cytopenias, sometimes the underlying disease is causing bone marrow fibrosis that may respond to treatment.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
